Ligand Q4 net income $18.2M ($1.03 diluted); reaffirms 2024 guidance

LIGAND PHARMACEUTICALS INC

2023-FY EPS reported $2.94 revenue$131,314,000

Q4 total revenue $28.1M (down from $50.4M in Q4 2022, which included $23.5M COVID Captisol sales); core adjusted EPS $1.05 vs $0.75.
Full-year 2023 royalties $83.9M (+16% YoY); core adjusted net income $71.7M ($4.06/diluted) vs $41.9M ($2.44).
2024 guidance reaffirmed: total revenue $130-142M, adjusted EPS $4.25-4.75.
FDA approved ZELSUVMI (berdazimer gel) for molluscum contagiosum; Merck's V116 vaccine granted priority review (PDUFA June 17, 2024).
Travere's FILSPARI sNDA for IgAN planned Q1 2024; FSGS data insufficient; Aldeyra received CRL for reproxalap.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LIGAND PHARMACEUTICALS INC reported financial results for the three and twelve months ended December 31, 2023.

Period: the three and twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000886163-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.